May 2025
Aldeyra hopes new data for dry-eye disease drug will satisfy FDA
United States Food and Drug Administration, Aldeyra, reproxalap, Approved, Dry Eye Syndromes, Clinical Trials, New Drug Application
Trump, FDA zero in on foreign factories to give domestic sites an edge
United States Food and Drug Administration, United States, Transplant Registry Unified Management Program, foreign factories, manufacturers
States sue US over plan for reorganization of federal health agencies
HHS reorganization, RFK Jr., lawsuit, mass layoffs, constitutionality, federal health agencies, state attorneys general
Brian Armstrongs NewLimit raises a $130M Series B, laying out road map for anti-aging drugs
NewLimit, Brian Armstrong, Coinbase CEO, anti-aging drugs, epigenetic reprogramming, Series B funding, Kleiner Perkins, genetic cell programming, healthy lifespan extension
Eli Lilly licenses early-stage ALS drug program from Alchemab in $415M pact
Amyotrophic Lateral Sclerosis, Alchemab, Eli, Eli Lilly
250 more NIH workers laid off, including cuts at the National Cancer Institute
NIH layoffs, National Cancer Institute, budget cuts, healthcare research, Trump administration, Department of Health and Human Services
‘Now is not the time to retreat’: BMS CEO blasts Trump admin tariffs, health reforms amid $40B US investment pledge
Bristol Myers Squibb, Trump tariffs, pharmaceutical manufacturing, domestic investment, pharmaceutical industry, US manufacturing, healthcare reform, pharmaceutical tariffs
Capricor shares turn red as FDA plans deramiocel adcomm, likely the first under new commissioner
United States Food and Drug Administration, Capricor, deramiocel, Market, Review [Publication Type], Biologics License Application, first
PTC crashes as win for Novartis-partnered Huntington’s drug fails to convince investors
factor IX, PTC518, Accelerated, Approved, United States Food and Drug Administration
Mersana makes Emi-Le the one, laying off 55% of staff to narrow focus to B7-H4 ADC
Emi-Le, Mersana, VTCN1 gene, Antibody-Drug Conjugates, emiltatug ledadotin, Malignant neoplasm of breast, 55%